Candesartan - CAS 139481-59-7
Catalog number:
139481-59-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C24H20N6O3
Molecular Weight:
440.45
COA:
Inquire
Targets:
Angiotensin Receptor
Description:
Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CV-11974
MSDS:
Inquire
1.Protective Role of Ramipril and Candesartan against Myocardial Ischemic Reperfusion Injury: A Biochemical and Transmission Electron Microscopical Study.
Sheik Uduman MS1, Reddy RB1, Punuru P1, Chakka G1, Karunakaran G2. Adv Pharmacol Sci. 2016;2016:4608979. doi: 10.1155/2016/4608979. Epub 2016 Mar 6.
The present study was designed to investigate the role of combined administration of Ramipril and Candesartan against in vitro myocardial ischemic reperfusion injury in rat. Male Wistar albino rats were divided into five groups (n = 6) and treated with saline (10 mL/kg), Ramipril (2 mg/kg), Candesartan (1 mg/kg), and the combination of both drugs, respectively 24 h before induction of global ischemia (5 min of stabilization, 9 min of global ischemia, and 12 min of reflow). Combination of Ramipril and Candesartan when compared to the monotherapy significantly increased the levels of superoxide dismutase, reduced glutathione, catalase, and nitric oxide and decreased the levels of thiobarbituric acid reactive substances. In addition, the superior protective role of combination of Ramipril and Candesartan on ischemia induced myocardial damage was further confirmed by well preserved myocardial tissue architecture in light microscopy and transmission electron microscopy analysis studies.
2.Candesartan cilexetil attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR.
Wang Z1, Niu Q2, Peng X3, Li M2, Liu K2, Liu Y2, Liu J2, Jin F2, Li X2, Wei Y4. Int J Cardiol. 2016 Apr 5;214:348-357. doi: 10.1016/j.ijcard.2016.04.007. [Epub ahead of print]
BACKGROUND: Left ventricular hypotrophy (LVH) is very common in hypertensives even after antihypertensive treatment. Mitofusin 2 (Mfn2) is a critical negative regulator of vascular smooth muscle cell (VSMC) hypertrophy by regulating mitochondrial fusion, ras/raf/MEK signal pathway, et al. The purpose of this study was to investigate whether candesartan attenuated cardiac remodeling by improving expression and function of mitofusin 2 in SHR.
3.Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S1, Reddy VA2, Arora S2, Patel K2. Drug Deliv Transl Res. 2016 Apr 29. [Epub ahead of print]
Candesartan cilexetil (CC), an ester prodrug of candesartan, is BCS class II drug with extremely low aqueous solubility limiting its oral bioavailability. The present research aimed to develop a nanocrystalline formulation of CC with improved saturation solubility in gastrointestinal fluids and thereby, exhibiting enhanced oral bioavailability. CC nanocrystals were prepared using a low energy antisolvent precipitation methodology. A combination of hydroxypropyl methylcellulose (HPMC) and Pluronic® F 127 (50:50 w/w) was found to be optimum for the preparation of CC nanocrystals. The particle size, polydispersity index (PDI), and zeta potential of optimized formulation was found to be 159 ± 8.1 nm, 0.177 ± 0.043, and -23.7 ± 1.02 mV, respectively. Optimized formulation was found to possess irregular, plate-like morphology as evaluated by scanning electron microscopy and crystalline as evaluated by differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Angiotensin Receptor Products


CGP 48369
(CAS: 135689-23-5)

Cgp 48369 is a nonpeptide a angiotensin type 1 receptor antagonist originated by Novartis. Treatmenf for for Hypertension in Switzerland was discontinued in 199...

PD 123177
(CAS: 114785-12-5)

PD 123177 is a Nonpeptide angiotensin type 2 receptor inhibitor. In Dec 1995, Preclinical development of it for cardiovascular disorders was began in USA.

CAS 160135-92-2 Gemopatrilat

Gemopatrilat
(CAS: 160135-92-2)

Gemopatrilat, an azepan derivative, has been found to be an angiotensin receptor as well as vasopeptidase inhibitor that was once studied against hypertension a...

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 124750-99-8 Losartan Potassium (DuP 753)

Losartan Potassium (DuP 753)
(CAS: 124750-99-8)

Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatati...

CAS 53902-12-8 Tranilast

Tranilast
(CAS: 53902-12-8)

Tranilast, also called Rizaben or Tranilastum, has anti-inflammatory and immunomodulatory effect. It binds to Aβ40 monomers and increases Aβ40 fibrillation.

Sacubitrilat
(CAS: 149709-44-4)

Sacubitrilat is one of the impurities of Sacubitril which has been found to be an endopeptidase inhibitor and be effective in the treatment of hypertension and ...

CAS 145216-43-9 Forasartan

Forasartan
(CAS: 145216-43-9)

Forasartan, a tetrazol derivative, has been found to be a angiotensin II receptor antagonist that could be effective against hypertension through influencing th...

CAS 130663-39-7 PD123319

PD123319
(CAS: 130663-39-7)

PD 123319 is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.

CAS 149690-05-1 Sacubitril sodium

Sacubitril sodium
(CAS: 149690-05-1)

Sacubitril, also known as AHU377, is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor b...

CAS 141887-34-5 A81988

A81988
(CAS: 141887-34-5)

A81988 is a potent, orally active angiotensin I1 antagonist with a long duration of action whose pharmacological profile has established it as an important tool...

CAS 144143-96-4 Eprosartan Mesylate

Eprosartan Mesylate
(CAS: 144143-96-4)

Eprosartan is a nonpeptide angiotensin II receptor antagonist, [3H]-eprosartan binds to the AT1 receptor with KD of 0.83 nM in rat vascular smooth muscle cells.

CAS 51833-78-4 Angiotensin I/II (1-7)

Angiotensin I/II (1-7)
(CAS: 51833-78-4)

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor, inducing vasorelaxation through release of NO and prostaglandins.

CAS 159748-08-0 LY285434

LY285434
(CAS: 159748-08-0)

An antagonist of angiotensin II receptor

CAS 114798-26-4 Losartan

Losartan
(CAS: 114798-26-4)

Losartan, an antagonist of angiotensin II receptor, could be effective in the treatment of hypertensive. IC50: 20nM.

BMS 183920
(CAS: 153072-33-4)

BMS 183920, a quinoline derivative, has been found to be an angiotensin II receptor antagonist that could have potential usage in antihypertensive study.

CAS 144689-63-4 Olmesartan Medoxomil

Olmesartan Medoxomil
(CAS: 144689-63-4)

Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist.

CAS 936623-90-4 LCZ696

LCZ696
(CAS: 936623-90-4)

LCZ696 is a potent ARNi inhibitor and an investigational drug to treat heart failure. Chemically, LCZ696 is a mixture of valsartan and sacubitril in a 1:1 mol...

CAS 247257-48-3 Fimasartan

Fimasartan
(CAS: 247257-48-3)

Fimasartan, also called as BR-A657, approved for the treatment of mild to moderate hypertension in South Korea, is a novel, non-peptide angiotensin II (Ang II) ...

Tranilast Sodium
(CAS: 104931-56-8)

Tranilast, an allergic media blocker, is effective for the treatment of asthma and is also used to treat asthma, allergic rhinitis and other allergic disorders.

Chemical Structure

CAS 139481-59-7 Candesartan

Quick Inquiry

Verification code

Featured Items